Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by bigmack1on May 07, 2021 2:19pm

237 Views

Post# 33153716

Funny coincidence

I was walking down the street in Toronto's east end today and noticed a dude sporting an Antibe Baseball Cap!

He had earbuds in, so I couldn't smoothly instigate a good chat. But it made me smile.

Great day for the longs today, much of the ish sentiment is behind us. Next stop, $6.00. PP Price.

A whiff of good news and we run.

<< Previous

Bullboard Posts

Next >>

Opawica seeks drill permits for Bazooka Gold Targets in Abitibi